Valvular heart disease associated with fenfluramine phentermine

New England Journal of Medicine

Volumn 337, Issue 9, 1997, Pages 581-588

  Connolly, Heidi M ^a   Crary, Jack L ^b   McGoon, Michael D ^a   Hensrud, Donald D ^a   Edwards, Brooks S ^a   Edwards, William D ^a   Schaff, Hartzell V ^a  

^a MAYO CLINIC   (United States)

^b MeritCare Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; FENFLURAMINE; PHENTERMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HUMAN; MALE; OBESITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; VALVULAR HEART DISEASE;

ADULT; AORTIC VALVE INSUFFICIENCY; APPETITE DEPRESSANTS; DRUG COMBINATIONS; FEMALE; FENFLURAMINE; HEART VALVE DISEASES; HUMANS; HYPERTENSION, PULMONARY; MIDDLE AGED; MITRAL VALVE; MITRAL VALVE INSUFFICIENCY; PHENTERMINE; TRICUSPID VALVE INSUFFICIENCY;

EID: 0030876952     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199708283370901     Document Type: Article

References (18)

1. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984;144:1143-8.
2. Langreth R. Critics claim diet clinics misuse obesity drugs. Wall Street Journal. March 31, 1997:B8.
3. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993;70: 537-41.
4. McMurray J, Bloomfield P, Miller HC. Irreversible pulmonary hypertension after treatment with fenfluramine. BMJ 1986;292:239-40.
5. Heuer L. Pulmonary hypertension. Chir Prax 1978;23:497.
6. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-16.
7. Weir EK, Reeve HL, Huang JM, et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996;94:2216-20.
8. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992;117:50-2.
9. Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients. Circulation 1993; 87:1188-96.
10. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790-5.
11. Beckett AH, Salmon JA. Pharmacokinetics of absorption, distribution and elimination of fenfluramine and its main metabolite in man. J Pharm Pharmacol 1972;24:108-14.
12. Tajik AJ, Seward JB, Hagler DJ, Mair DD, Lie JT. Two-dimensional real-time ultrasonic imaging of the heart and great vessels: technique, image orientation, structure identification, and validation Mayo Clin Proc 1978;53:271-303.
13. Nishimura RA, Miller FA Jr, Callahan MJ, Benassi RC, Seward JB, Tajik AJ. Doppler echocardiography: theory, instrumentation, technique, and application. Mayo Clin Proc 1985;60:321-43.
14. Mitchell P, Smythe G. Hormonal responses to fenfluramine in depressed and control subjects. J Affect Disord 1990;19:43-51.
15. Thorson ÅH. Endocardial sclerosis and other heart lesions in the carcinoid disease. Acta Med Scand Suppl 1958;334:99-119.
16. Redfield MM. Ergot alkaloid heart disease. In: Hurst JW, ed. New types of cardiovascular diseases: topics in clinical cardiology. New York: Igaku-Shoin Medical, 1994:63-76.
17. Morita T, Mehendale HM. Effects of chlorphentermine and phentermine on the pulmonary disposition of 5-hydroxytryptamine in the rat in vivo. Am Rev Respir Dis 1983;127:747-50.
18. Klein AL, Burstow DJ, Tajik AJ, et al. Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers. J Am Soc Echocardiogr 1990;3:54-63.